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WOMAN WITH RELAPSING FEVERS
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Case Presentation
A 50 year-old Nigerian woman with a past medical history
significant for type II diabetes and hypertension presented to the
ED with a chief complaint of recurrent fevers and chills. The
patient was in her usual state of health until approximately 6 weeks
prior to admission, while during a visit with family in Nigeria she
noted the onset of high fevers and general malaise. Initially, her
fevers occurred daily for a period of one week, and were associated
with chills, fatigue, loss of appetite, and myalgias. During this time,
she was not evaluated by a physician, nor did she take any
medication. Her symptoms seemed to resolve however, and she
felt reasonably well. She then returned home to the United States,
approximately 4 weeks prior to admission. Upon return, she again
experienced one week of recurring fevers/chills, as well as the above
generalized symptoms. With no evaluation or intervention, her
symptoms improved. Two weeks later, the same pattern of
symptoms returned and the patient reported to the ED.

Figure 1.

Upon presentation, the patient complained of subjective high
fevers, shaking chills, anorexia, fatigue, generalized weakness,
myalgias, and 15 pound weight loss during the prior 6 weeks. She
denied sick contacts and known TB exposures. She traveled with
her son, who remained in his usual state of health. She reported
that the areas to which she traveled were heavily mosquito-infested.
Her past medical history was significant for type II diabetes and
hypertension. Her home medications included metformin 500
mg twice daily and diovan/HCTZ 160/25 once daily. There were
no recent medication changes and she denied drug allergies. She
had no history of alcohol, tobacco, or substance abuse. Her
mother and father were both alive and well, living in Nigeria. She
is employed as a chef, but had not been to work since before her
visit to Nigeria.

Figure 2.

Physical exam revealed a well-nourished woman in no apparent
distress. Her temperature was 102.8; pulse 88 beats/minute; blood
pressure 144/78 mm Hg; respiratory rate 16 breaths/minute; and
pulse ox 100% on room air. Her sclera were anicteric and mucous
membranes were dry. She had a normal S1S2, with a regular rate
and rhythm, and no murmurs, rubs, or gallops. Her lungs were
clear to auscultation bilaterally and she had no peripheral edema.
Her abdomen was soft, non-tender, non-distended, with no
hepatosplenomegaly. Her neurologic exam was non-focal; she was
awake, alert, and oriented to person, place, and time.
Laboratory evaluation showed a normal complete blood count,
chemistry panel, and liver function panel. A urinalysis revealed
trace protein and trace ketones. Her EKG showed NSR with no
ischemic changes. A blood smear was reviewed and revealed intraerythrocytic ringforms consistent with Plasmodium (Figures 1
and 2). A diagnosis of malaria was made and the patient was
immediately started on quinine and doxycycline. Despite oral
therapy, the patient was admitted to the hospital to follow her
fever curve and await speciation. The patient remained afebrile
after ~ 36 hours of antibiotic therapy. The microbiology lab
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Figure 3.
performed a Giemsa stain of thin and thick smears, revealing
Plasmodium falciparum with a 20% parasitemia level. Her labs
were followed in house as well, with no evidence of renal
compromise or LFT abnormalities. She was discharged home to
complete a 7 day course of quinine and doxycycline.
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increased resistance of the Anopheles mosquito to insecticides,
climate changes, and increased travel to endemic regions. Globally,
the areas of greatest transmission include Oceania and sub-Saharan
Africa; other regions with high risk of transmission, in descending
order, are the Indian subcontinent, Southeast Asia, South America,
and Central America. Travelers from industrialized countries are at
risk for malaria as well; approximately 30,000 of them contract the
disease each year. Worldwide, an alarming 700,000 to 2.7 million
deaths occur each year.

Figure 4.

Malaria transmission occurs predominantly via a bite from the female
Anopheles mosquito. There are other rare means of transmission,
including congenital acquisition, blood transfusion, needle sharing,
and organ transplant. In the United States, Anopheles mosquitoes
are present in all states, except Hawaii. Although extremely rare,
mosquito-borne transmission in the US has occurred. An outbreak
of malaria was reported in West Palm Beach, Florida in 2003, with 7
documented cases of Plasmodium vivax infection.
There are four species of Plasmodia: P. falciparum, P. vivax, P.
ovale, and P. malariae. Human infection by each of them occurs
when sporozoites are transmitted from an infected anopheline
mosquito during a bite. The sporozoites travel via the bloodstream
to the liver, where they invade hepatocytes and divide thousands
of times into mature tissue schizonts. Each schizont contains
thousands of daughter merozoites. After 6-16 days, the liver
schizonts rupture, releasing merozoites into the bloodstream
where they invade red blood cells.

Figure 5.

Within the RBCs, merozoites mature from ring forms to
trophozoites to mature red cell schizonts (asexual); daughter
merozoites are then released and able to infect new red cells. Some
merozoites will differentiate into male and female gametocytes
(sexual) which circulate in the bloodstream until they are ingested
by a blood-feeding anopheline mosquito. Sporozoites then form
in the mosquito and will eventually reinfect humans.
Mosquito-transmitted P. vivax and P. ovale infections carry a
unique risk; some parasites remain dormant in the liver and may
cause late relapse by reactivating after several months.
The pathogenesis of malaria is several-fold. All four species may
cause anemia via alteration of red cell membranes resulting in
hemolysis, accelerated splenic clearance, and digestion of red cell
proteins and hemoglobin. Additionally, red cell lysis releases
tumor necrosis factor alpha, which in turn suppresses
hematopoiesis. Thrombocytopenia may result from increased
splenic sequestration and decreased platelet survival time.

Figure 6.

Discussion
Approximately 300 to 500 million cases of malaria occur annually
worldwide, particularly in children living in tropical developing
countries. Infection rates have increased in recent years, secondary
to factors including increased resistance of parasites to drug therapy,

P. falciparum may cause especially severe or fatal disease via
formation of “sticky knobs” on the surface of erythrocytes. These
may bind to receptors on endothelial cells in capillaries and
venules, leading to sequestration and subsequent obstruction to
blood flow, which can result in secondary organ dysfunction.
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Several genetic factors have been suggested as protective
mechanisms against severe infection. For example, presence of the
sickle cell trait has been shown to lower the risk of P. falciparum
malaria, lower parasite densities, and lower rates of hospital
admissions. Alpha and beta thalassemia have been shown to be
associated with decreased rates of parasite multiplication, as well.
Individuals who live in endemic areas may develop partial immunity
to disease after repeated infections; they become “semi-immune.”
This does not completely prevent infection however; after a bite
from an infected mosquito, they will develop parasitemia, but the
severity of symptoms may be less. This partial immunity often wanes
after leaving an endemic area. Therefore, when these individuals
return home to endemic areas, they must take prophylaxis.
Malaria infections usually become symptomatic during the
erythrocytic stage of the parasite life cycle; incubation periods for
P. falciparum are usually 12 to 14 days, 2 months for P. vivax and
P. ovale, and finally 35 days for P. malariae. The erythrocytic stage
of infection usually lasts approximately one to four weeks.
Malarial signs and symptoms may vary, but essentially all infected
patients exhibit fever; it develops with the release of merozoites
from rupture red blood cells. Fevers occur in paroxysms which
are often daily and irregular. Other common symptoms may
include chills, sweats, headache, myalgias, fatigue, nausea,
vomiting, abdominal pain, diarrhea, and cough. Signs of infection
may include anemia, thrombocytopenia, splenomegaly,
hepatomegaly, and jaundice. Nephrotic syndrome occurs in some
cases, and is most commonly associated with P. malariae.
P. falciparum in particular has been noted to have severe morbidity
and mortality. Untreated falciparum infections can be fatal. This
species has the ability to invade red cells of all ages, thereby allowing
high levels of parasitemia, sometimes involving more than 50% of
red cells. As noted above, P. falciparum is more likely to lead to
secondary end organ damage than the other species because of its
ability to adhere to blood vessels and create obstruction to flow.
Cerebral malaria is one rare, but potentially fatal effect of the
infection. It usually presents with an impaired state of consciousness
or seizures, and may result in coma or death; 20% of treated adults
and 15% of children may die. Other complications of P. falciparum
include oliguric renal failure, pulmonary edema/ARDS,
hypoglycemia, anemia, and gastroenteritis.
Conventionally, malaria has been diagnosed by light microscopy
of a Giemsa-stained thick and/or thin blood smear; this is the
gold standard. The thick smear is more sensitive in the diagnosis
of malaria, however the thin smear facilitates exam of the parasite
morphology which aids in species identification. The thin smear
is also used to quantify the percentage of parasitized red cells.
PCR-based techniques are also available; they detect nucleic acid
sequences specific to Plasmodium species and are helpful when
light microscopy is equivocal in species identification. The
sensitivity and specificity of PCR approach 100 percent. Other
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antigen detection methods and serologic assays are available, but
their sensitivity decreases with lower levels of parasitemia.
Most patients with P. vivax, P. ovale, and P. malariae can be treated
as outpatients. Those with P. falciparum however, should be
admitted to the hospital for initiation of their treatment and
observation for any evidence of complications. None of the
available anti-malarial drugs act on all stages of the malaria life
cycle to kill the parasite; therefore, patients require multi-drug
regimens. Choosing an appropriate regimen depends upon the
species and pattern of drug resistance.
P. ovale, P. malariae, and chloroquine-sensitive P. vivax can be
treated with oral chloroquine, with cure rates exceeding 95 percent.
Patients with chloroquine-resistant P. vivax may be treated with a
combination of mefloquine or quinine sulfate and doxycycline. In
P. vivax and P. ovale infection, relapse after chloroquine therapy is
common secondary to the presence of liver hypnozoites lying
dormant. Therefore, primaquine should be given to all of these
patients for fourteen days, immediately after finishing their course
of chloroquine. All patients must be screened for G6PD deficiency
before starting primaquine therapy to avoid hemolysis.
Chloroquine-resistant falciparum is now widespread throughout
most countries; therefore, P. falciparum infections should be
presumed to be chloroquine-resistant in almost all cases. The most
commonly recommended regimen for this is oral quinine plus
pyrimethamine-sulfadoxine or doxycycline for seven days. An
alternative is quinine plus clindamycin, particularly for pregnant
women or young children. Quinine-based regimens have greater
than 90 percent efficacy in most parts of the world, except
Southeast Asia where resistance is prevalent. There are alternative
regimens as well, including mefloquine, atovaquone-proguanil,
and artemisinin derivatives.
It is essential to stress the importance of taking chemoprophylaxis
when patients travel to endemic areas. Most cases of malaria in
the US are in patients who have not taken prophylaxis or those
who have stopped taking it too soon after return home.
Chloroquine should be used for areas where there is no
chloroquine-resistant P. falciparum; it should be started 1-2 weeks
before the patient departs and continued for 4-6 weeks after
leaving the endemic area. Travelers to chloroquine-resistant areas
should take mefloquine for prophylaxis. After travel to areas with
P. vivax and P. ovale, patients should take primaquine during the
last two weeks of a prophylaxis period.
■
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